pharma news today obesity glp-1 New Pill Foundayo (Orforglipron) Gets FDA Approval for Data Brief: GLP-1 Prescriptions for

Evidence-based complementary Altern

Supplementary information Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material

Why people switch The most common reasons include weight loss plateaus, inadequate response at maximum dose, side effect intolerance, cost or insurance changes, and desire for greater efficacy

Further funding was sought and from 1 August 2019 an investigator led grant was obtained from Invex Therapeutics

Its not just about motivation or discipline